Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
Autoimmune lymphoproliferative syndrome (ALPS) is a rare, newly recognized, chronic lymphoproliferative disorder in children and is characterized by lymphadenopathy, splenomegaly, pancytopenia, autoimmune phenomena and expansion of double-negative (DN) T lymphocytes (TCR alpha beta+, CD4-, CD8-). Defective lymphocyte apoptosis caused by mutations of the Fas (CD95) gene has been linked in the pathogenesis of ALPS, as binding of Fas-ligand to Fas can trigger apoptosis. Of the ALPS cases reported to date, point mutations, frameshifts and silent mutations in Fas all have been identified. We report two new point mutations in Fas in a child with ALPS and eosinophilia; studies on other family members established the pattern of inheritance for these mutations. Flow cytometric analysis of blood and tissues (spleen, lymph node, bone marrow) revealed abnormally expanded populations of DN T lymphocytes. Furthermore, activated lymphocytes and IFN gamma-activated eosinophils were resistant to Fas-mediated apoptosis. Eosinophil resistance to Fas-mediated apoptosis has not been previously described in ALPS. Sequencing of Fas revealed two separate mutations not previously reported. One mutation, a C to T change at base 836, was a silent mutation inherited from the mother, while the second mutation, a C to A change at base 916, caused a non-conservative amino acid substitution in the death domain of Fas, changing a threonine to a lysine. This mutation is associated with a predicted change in the structure of a part of the death domain from a beta-pleated sheet to an alpha-helix. We speculate that the mutation in the death domain prevents the interaction of Fas with intracellular mediators of apoptosis and is responsible for the autoimmune manifestations of ALPS and the abnormal lymphocytosis and eosinophilia in this patient.
Aspinall
A I
AI
Immunology Research Group, University of Calgary, Canada.
Pinto
A
A
Auer
I A
IA
Bridges
P
P
Luider
J
J
Dimnik
L
L
Patel
K D
KD
Jorgenson
K
K
Woodman
R C
RC
D000328:Adult; D017209:Apoptosis / Q000235:genetics; D001327:Autoimmune Diseases / Q000235:genetics* / Q000473:pathology; D015704:CD4 Antigens / Q000032:analysis; D016827:CD8 Antigens / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D018076:DNA, Complementary / Q000737:chemistry; D004802:Eosinophilia / Q000235:genetics* / Q000473:pathology; D006650:Histocompatibility Testing; D006801:Humans; D008206:Lymphatic Diseases / Q000235:genetics / Q000473:pathology; D016131:Lymphocyte Subsets / Q000378:metabolism; D008232:Lymphoproliferative Disorders / Q000235:genetics* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010375:Pedigree; D013163:Splenomegaly / Q000235:genetics / Q000473:pathology; D013577:Syndrome; D013921:Thrombocytopenia / Q000235:genetics / Q000473:pathology; D019014:fas Receptor / Q000235:genetics*
D015704:CD4 Antigens; D016827:CD8 Antigens; D018076:DNA, Complementary; D019014:fas Receptor